Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger to create a company with about $2.2 billion in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.
Merger Details
The combined company will have 11 marketed medicines for conditions including opioid addiction, epilepsy, migraine, Parkinson’s disease and attention-deficit hyperactivity disorder. The companies expect about $125 million in annual cost savings.
Supernus shareholders will receive 1.5401 Indivior shares for each share held. Indivior shareholders will own about 56.5% of the combined company, while Supernus shareholders will hold the rest.
The combined company will be named Supernus, Inc and led by Supernus CEO Jack Khattar. Together they are expected to have about $878 million in net debt.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
